THL Partners to Acquire Pharmaceutical Research Organization Celerion From H.I.G. Capital

Paul, Weiss is advising THL Partners on the financing aspects of THL’s acquisition of leading early-stage clinical research organization Celerion from an affiliate of H.I.G. Capital. Under the agreement, THL will, through its flagship Fund IX, make a majority investment in Celerion, which focuses on clinical pharmacology and bioanalytical sciences. The transaction is expected to close in 2026, subject to customary closing conditions. Financial details were not disclosed.

The Paul, Weiss team is led by corporate partners Eric Wedel, Matthew Leist and Caroline Epstein.